Home | Publications | Diseases | Cancer place holder
place holder place holder

Cancer

Pipeline Insight Therapeutic Cancer Vaccines

A turbulent path from bench to bedside

Publication Date   October 2007
Publisher   Datamonitor
Product Type   Report
Pages   159
ISBN Number   not applicable
Product Code   DAT608
Ask a question about this product?

Price £3,010.00

approximately: $4,470 | €3,542

Summary


This analysis examines the historical and forecast performance for Organon in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Content


  • Chapter 1 Executive Summary
    • Key Findings
    • Historical And Forecast Ethical Sales Performance
    • Therapeutic Strategy
    • Launch And Expiry Outlook
    • Externalization, Geographic And Molecule Type Strategies
    • Externalization Strategy
    • Geographic Strategy
    • Molecule Type Strategy
    • Swot Analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Chapter 2 Corporate History
    • Key Findings
    • Background
    • Key Corporate Developments
    • Imminent Ipo Diverted Following Schering-Plough's Entry Into The Fray
    • M&A History
    • M&A Strategy
    • Organon M&A
    • Current Corporate Structure
    • Current Management Team
  • Chapter 3 Historical Performance
    • Key Findings
    • Introduction
    • Revenue And Growth Rate Analysis, 2001-06
    • Revenue And Growth Rate Vs. Peer Set
    • Product Analysis, 2001-06
    • Growth Drivers
    • Nuvaring
    • Puregon
    • Growth Resistors
    • Remeron
    • Livial
    • Operating Revenue And Cost Analysis, 2001-06
    • Operating Revenue/Cost Analysis
  • Chapter 4 Forecast Performance
    • Key Findings
    • Introduction
    • Revenue And Growth Rate, 2006-12
    • Product Analysis, 2006-12
    • Growth Drivers
    • Asenapine
    • Sugammadex
    • Org 50081 (Insomnia)
    • Nuvaring
    • Implanon
    • Growth Resistors
    • Esmeron
    • Livial
    • Therapy Area Analysis, 2006-12
    • Central Nervous System
    • Urology & Sexual Health
    • Therapy Area Focus
    • Launches And Expiries Analysis, 2006-12
    • Launch Portfolio
    • Core Portfolio
    • Expiry Portfolio
    • Launch/Core/Expiry Configuration
    • Externalization Analysis, 2006-12
    • Geographic Analysis, 2006-12
    • Molecule Type Analysis, 2006-12
  • Chapter 5 Key Products And Competitors
    • Key Findings
  • Overview
    • Women's Health
    • Nuvaring
  • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Another Strong Year For Organon's Number One Growth Driver
    • Promotional Drive Remains Key Factor In Nuvaring's Uptake
    • Contraceptive Market Overview
    • Future Market Assessment
    • Puregon
  • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Current Market Assessment
    • Future Market Assessment
    • Implanon
  • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Current Market Assessment
    • Future Market Assessment
    • Nomac/E2
  • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Future Market Assessment
    • Org 32686
  • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Future Market Assessment
    • Cns
    • Asenapine
  • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Future Market Assessment
    • Sugammadex
  • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Clinical Trial Progression
    • Future Market Assessment
    • Remeron
  • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Current Market Assessment
    • Future Market Assessment
    • Org 50081 (Insomnia)
  • Overview
    • Sales Forecast
    • News Flow
    • Clinical Trial Progression
    • Current Market Assessment
    • Future Market Assessment
    • Esmeron/Zemuron
  • Overview
    • Sales Forecast
    • News Flow
    • Competitive Landscape
    • Current Market Assessment
    • Future Market Assessment
    • R&D Pipeline
  • Chapter 6 Appendix
    • Ims Vs. Company-Reported Data Reconciliation
    • References
    • Abbreviations
    • Exchange Rates
  • List Of Tables
    • Table 1: Organon Biosciences Executive Committee
    • Table 2: Peer Set Overview
    • Table 3: Operating Revenue/Cost Analysis ($M), 2001-06
    • Table 4: Operating Cost Ratio Analysis (% Of Total Revenues), 2001-06
    • Table 5: Product Portfolio Overview, Sales ($M), 2006-12
    • Table 6: Therapy Area Overview, Sales ($M), 2006-12
    • Table 7: Launch Portfolio Overview, Sales ($M), 2006-12
    • Table 8: Core Portfolio Overview, Sales ($M), 2006-12
    • Table 9: Expiry Portfolio Overview, Sales ($M), 2006-12
    • Table 10: Externally Developed Portfolio ($M), 2006-12
    • Table 11: Molecule Type Overview, Sales ($M), 2006-12
    • Table 12: Key Products Overview
    • Table 13: Nuvaring: Overview
    • Table 14: Nuvaring: Sales Forecast ($M), 2006-12
    • Table 15: Nuvaring: News Flow
    • Table 16: Organon's Non-Dtc Marketing Expenditure In 2006
    • Table 17: Top 10 Contraceptive Products In 2006 (7mm)
    • Table 18: Puregon/Follistim: Overview
    • Table 19: Puregon/Follistim: Sales Forecast ($M), 2006-12
    • Table 20: Puregon/Follistim: News Flow
    • Table 21: Implanon: Overview
    • Table 22: Implanon: Sales Forecast ($M), 2006-12
    • Table 23: Implanon: News Flow
    • Table 24: Nomac/E2: Overview
    • Table 25: Nomac/E2: Sales Forecast ($M), 2006-12
    • Table 26: Nomac/E2: News Flow
    • Table 27: Org 32686: Overview
    • Table 28: Org 32686: Sales Forecast ($M), 2006-12
    • Table 29: Org 32686: News Flow
    • Table 30: Asenapine: Overview
    • Table 31: Asenapine: Sales Forecast ($M), 2006-12
    • Table 32: Asenapine: News Flow
    • Table 33: Sugammadex: Overview
    • Table 34: Sugammadex: Sales Forecast ($M), 2006-12
    • Table 35: Sugammadex: News Flow
    • Table 36: Remeron: Overview
    • Table 37: Remeron: Sales Forecast ($M), 2006-12
    • Table 38: Remeron: News Flow
    • Table 39: Org 50081 (Insomnia): Overview
    • Table 40: Org 50081 (Insomnia): Sales Forecast ($M), 2006-12
    • Table 41: Org 50081 (Insomnia): News Flow
    • Table 42: Esmeron: Overview
    • Table 43: Esmeron/Zemuron: Sales Forecast ($M), 2006-12
    • Table 44: Esmeron/Zemuron: News Flow
    • Table 45: Organon's R&D Pipeline (Phase I-Registration)
    • Table 46: Exchange Rates, 2006
  • List Of Figures
    • Figure 1: Historical And Forecast Ethical Sales Performance (% Cagr), Organon And Mid Pharma Peer Set
    • Figure 2: Therapeutic Focus Vs. Mid Pharma Peer Set (%), 2006
    • Figure 3: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Organon
    • Figure 4: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Peer Set
    • Figure 5: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2006
    • Figure 6: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2012
    • Figure 7: Swot Analysis Of Organon
    • Figure 8: M&A/Divestment History
    • Figure 9: Current Corporate Structure
    • Figure 10: Revenue & Growth Rate (Ethical Sales) ($M), 2001-06
    • Figure 11: Ethical Revenue ($M) And Growth Rate (%) Vs. Peer Set, 2001-06
    • Figure 12: Growth Drivers/Resistor Products Of Historical Revenue Performance ($M), 2001-06
    • Figure 13: Operating Revenue/Cost Analysis ($M), 2001-06
    • Figure 14: Operating Cost Ratio Analysis (% Of Total Revenues), 2001-06
    • Figure 15: Ethical Revenue ($M) And Growth Rate (%), 2006-12
    • Figure 16: Top Five Products By Sales ($M), 2006
    • Figure 17: Top Five Products By Sales ($M), 2012
    • Figure 18: Growth Drivers And Resistors By Product, 2006-12
    • Figure 19: Key Strategic Products, Sales ($M), 2006-12
    • Figure 20: Ethical Sales By Therapy Area ($M), 2006-12
    • Figure 21: Growth Drivers And Resistors By Therapy Area (%), 2006-12
    • Figure 22: Ethical Sales By Therapy Area (%), 2006-12
    • Figure 23: Therapy Area Focus Compared With Peer Set (% Total Ethical Sales), 2006
    • Figure 24: Therapy Area Focus Compared With Peer Set (% Total Ethical Sales), 2012
    • Figure 25: Launch Schedule, Sales ($M), 2006-12
    • Figure 26: Core Products Sales Growth ($M), 2006-12
    • Figure 27: Expiry Schedule, Sales ($M), 2006-12
    • Figure 28: Launch, Core And Expiry, Sales ($M), 2006-12
    • Figure 29: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Organon
    • Figure 30: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Peer Set
    • Figure 31: Externalization Dependency, Sales ($M), 2006-12
    • Figure 32: Growth Drivers And Resistors, Externally Vs. Internally Discovered Products, Sales ($M), 2006-12
    • Figure 33: Externalization Dependency Vs. Peer Set, % Total Sales, 2006
    • Figure 34: Externalization Dependency Vs. Peer Set, % Total Sales, 2012
    • Figure 35: Geographical Sales Breakdown ($M), 2006-12
    • Figure 36: Growth Drivers And Resistors By Geography, Sales ($M), 2006-12
    • Figure 37: Us Dependency Vs. Peer Set, % Total Sales, 2006
    • Figure 38: Us Dependency Vs. Peer Set, % Total Sales, 2012
    • Figure 39: Molecule Type Sales Breakdown ($M), 2006-12
    • Figure 40: Growth Drivers And Resistors By Molecule Type, Sales ($M), 2006-12
    • Figure 41: Biologics Dependency Vs. Peer Set, % Total Sales, 2006
    • Figure 42: Biologics Dependency Vs. Peer Set, % Total Sales, 2012
    • Figure 43: Quarterly Sales Of Top Five Contraceptives Over 2006 ($M)
    • Figure 44: Puregon Vs. Gonal-F, Quarterly Sales ($M), 2003-06
    • Figure 45: Us Mirtazapine Sales ($M), 2002-06
    • Figure 46: 6mm Mirtazapine Sales ($M), 2002-06
    • Figure 47: Ims Vs. Company-Reported Ethical Sales Discrepancy ($M), 2006
    • Figure 48: Ims Vs. Company-Reported Ethical Sales Forecast Growth Rates (%), 2006-12